Abstract
The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Current Pharmaceutical Design
Title:Why do Psychotic Patients use Cannabis? Case Series
Volume: 18 Issue: 32
Author(s): Anna Kolliakou, Khalida Ismail and Zerrin Atakan
Affiliation:
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Abstract: The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Export Options
About this article
Cite this article as:
Kolliakou Anna, Ismail Khalida and Atakan Zerrin, Why do Psychotic Patients use Cannabis? Case Series, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884807
DOI https://dx.doi.org/10.2174/138161212802884807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Introduction to 'Beneficial Effects of Psychedelics with a Special Focus on Addictions')
Current Drug Abuse Reviews Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Structure, Activities and Biomedical Applications of Human Butyrylcholinesterase
Protein & Peptide Letters Formononetin Ameliorates Cognitive Disorder via PGC-1α Pathway in Neuroinflammation Conditions in High-Fat Diet-Induced Mice
CNS & Neurological Disorders - Drug Targets Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Changes in Speech Chunking in Reading Aloud is a Marker of Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
CNS & Neurological Disorders - Drug Targets Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science The Orexinergic (Hypocretin) System and Nociception: An Update to Supraspinal Mechanisms
Current Medicinal Chemistry Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets Projecting Dynamic Trends for HIV/AIDS in a Highly Endemic Area of China: Estimation Models for Liangshan Prefecture, Sichuan Province
Current HIV Research Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats
Current Alzheimer Research Perspectives in Cell Cycle Regulation: Lessons from an Anoxic Vertebrate
Current Genomics Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Peptides as Modulators of α-Synuclein Aggregation
Protein & Peptide Letters Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets